J Cardiovasc Comput Tomogr
July 2024
Background: Age and frailty are associated with underuse of anticoagulation in elderly patients with atrial fibrillation (AF).
Objectives: This study aimed at assessing major clinical outcomes in very elderly patients with AF treated with recommended dose edoxaban and look for a possible relation with frailty measured by a validated score.
Methods: This prospective multicenter cohort study enrolled consecutive very elderly (age ≥80 years) anticoagulation-naïve patients starting recommended doses of edoxaban.